Graham supports client projects providing expert interpretation of data including prediction, modelling and simulation of PK and PK/PD. His role allows clients to make informed decisions to maximise the probability of their success in choosing the right compounds and dose.
Graham joined XenoGesis in 2015, bringing over 14 years’ industrial drug discovery experience, as well as a track record of delivering pre-clinical drug candidates in oncology and inflammation through integration of DMPK properties into compound design to increase the probability of creating successful drugs.
Prior to joining XenoGesis, Graham worked at UCB for 8 years before joining Almac Discovery in 2009. As Director of Medicinal Chemistry, he was responsible for medicinal chemistry strategy across all projects including integration of DMPK properties into design and progression of compounds.
Graham graduated from the University of Nottingham with a PhD in Synthetic Organic Chemistry and went on to complete his Postdoctoral Research at the University of Geneva.